Showing results (151-160 of 379) with videos related to

Sort By:
Pageof 38
Diabetes, Obesity & Metabolism|August 17, 2021
Reasons for hospitalizations in patients with type 2 diabetes in the CANVAS programme: A secondary analysisKent Y Feng, JingWei Li, Juliana Ianus, et al.
Diabetes, Obesity & Metabolism|May 15, 2023
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trialsVikas S Sridhar, Brendon L Neuen, Robert A Fletcher, et al.
Diabetes, Obesity & Metabolism|March 1, 2017
Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsBruce Neal, Vlado Perkovic, Kenneth W Mahaffey, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 6, 2012
Outcomes of extended-hours hemodialysis performed predominantly at homeMin Jun, Meg J Jardine, Nicholas Gray, et al.
European Journal of Heart Failure|January 23, 2025
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trialsSafia Chatur, Muthiah Vaduganathan, Robert A Fletcher, et al.
European Heart Journal|May 27, 2010
Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney diseaseHiddo J Lambers Heerspink, Toshiharu Ninomiya, Vlado Perkovic, et al.
JACC. Heart Failure|November 3, 2019
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 DiabetesJingWei Li, Mark Woodward, Vlado Perkovic, et al.
International Journal of Cardiology|September 26, 2020
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trialsJie Yu, Zien Zhou, Kenneth W Mahaffey, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|November 4, 2022
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosisVandana S Mathur, David A Bushinsky, Lesley Inker, et al.
Nephrology (Carlton, Vic.)|June 6, 2020
No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trialBrendan Smyth, Li Zuo, Nicholas A Gray, et al.
Pageof 38